Parkinson's Disease Market Report 2026

The parkinson's disease market size has grown strongly in recent years. It will grow from $3.62 billion in 2025 to $3.92 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to limited treatment options for disease progression, reliance on levodopa-centric therapy, delayed diagnosis due to symptom overlap, lack of specialized movement disorder clinics, uneven access to advanced surgical interventions.

The parkinson's disease market size is expected to see strong growth in the next few years. It will grow to $5.32 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to development of novel dopamine and non-dopamine therapies, increasing prevalence of aging population, rising adoption of deep brain stimulation procedures, growing focus on personalized medicine approaches, expansion of neurology specialty clinics. Major trends in the forecast period include rising adoption of combination drug therapies, increasing use of deep brain stimulation procedures, growth of early-stage diagnosis and intervention, expansion of multidisciplinary parkinson’s care programs, improved symptom management through personalized treatment plans.

The growing prevalence of neurodegenerative diseases is expected to drive the expansion of the Parkinson's disease market going forward. Neurodegenerative diseases are a group of conditions marked by the gradual deterioration and loss of neuronal function in the brain and nervous system. The rising occurrence of these diseases is attributed to factors such as an aging global population, genetic susceptibility, environmental influences, improved diagnostic capabilities, increasing chronic health conditions, and lifestyle-related changes. Parkinson’s disease contributes to a deeper understanding of neurodegenerative disorders by offering valuable insights into disease mechanisms, identifying potential therapeutic targets, and supporting the development of innovative treatment strategies. For example, in 2025, the National Institutes of Health (NIH), a US-based government medical research agency, projected that the prevalence of Parkinson’s disease by 2050 would reach approximately 267 cases per 100,000 people, with estimates ranging from 230 to 320. Therefore, the rising prevalence of neurodegenerative diseases is fueling the growth of the Parkinson's disease market.

Companies operating in the Parkinson’s disease market are increasingly concentrating on developing advanced treatment solutions, such as levodopa-based therapies, to enhance motor function and ensure continuous symptom control for patients with advanced Parkinson’s disease. Levodopa-based therapy uses levodopa, which is converted into dopamine in the brain, to improve motor performance and reduce disease symptoms. For instance, in October 2024, AbbVie Inc., a US-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for VYALEV, a combination therapy containing levodopa and carbidopa designed for Parkinson’s disease treatment. The formulation improves levodopa effectiveness by preventing its breakdown before reaching the brain, thereby increasing dopamine availability. This therapy effectively manages motor symptoms such as tremors, rigidity, and bradykinesia, helping patients perform daily activities more easily. It is regarded as a key therapeutic option for individuals experiencing motor fluctuations associated with Parkinson’s disease.

In August 2024, AbbVie Inc., a US-based pharmaceutical company, acquired Cerevel Therapeutics Holdings Inc. for an undisclosed amount. Through this acquisition, AbbVie strengthened its neuroscience portfolio and addressed unmet needs in neurological and psychiatric disorders. Cerevel Therapeutics Holdings Inc. is a US-based biotechnology company focused on developing treatments for Parkinson’s disease.

Major companies operating in the parkinson's disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

North America was the largest region in the parkinson's disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson's disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the parkinson's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the parkinson’s disease market by increasing costs for imported pharmaceutical ingredients, advanced drug formulations, and neuromodulation devices used in treatment and management. Hospital pharmacies, clinics, and specialty neurology centers in north america, europe, and asia-pacific are most affected due to dependence on global supply chains. These tariffs can lead to higher treatment costs and delayed availability of advanced therapies. However, they also encourage local drug manufacturing, regional production of medical devices, and supply chain diversification, supporting long-term market stability.

The parkinson's disease market research report is one of a series of new reports that provides parkinson's disease market statistics, including parkinson's disease industry global market size, regional shares, competitors with a parkinson's disease market share, detailed parkinson's disease market segments, market trends and opportunities, and any further data you may need to thrive in the parkinson's disease industry. This parkinson's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Parkinson’s disease is a progressive neurological condition that affects movement as a result of the degeneration of dopamine-producing cells in the brain. It commonly leads to symptoms such as tremors, muscle rigidity, slowed movements, and difficulties with balance and coordination. Management of the disease typically includes medications like levodopa to reduce symptoms, along with physical therapy and, in some cases, surgical options such as deep brain stimulation.

The main drug classes used for the treatment of Parkinson’s disease include dopamine agonists, catechol-O-methyltransferase inhibitors, monoamine oxidase B inhibitors, anticholinergics, carbidopa-levodopa, and others. Dopamine agonists are drugs that replicate the action of dopamine in the brain, thereby helping to control disease symptoms. These medications are administered through routes such as oral, injectable, intestinal infusion, subcutaneous, and other methods, depending on therapeutic requirements. Parkinson’s disease drugs are distributed through retail pharmacies, hospital pharmacies, and online pharmacies to ensure wide availability. Treatment is primarily delivered in clinics and hospitals, where patients can be regularly monitored and managed by healthcare professionals.

The parkinson's disease market consists of revenues earned by entities providing services such as speech therapy, and physical therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The parkinson's disease market also includes sales of amantadine and adenosine A2A receptor antagonists. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.